Stocks · News reference
Filed: 2026-09-04 AccNo: 0001493152-26-041533 Size: 640 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
CDT Equity Inc. (Nasdaq: CDT) announced 13.7 million shares outstanding as of August 31, 2026, with a market capitalization of approximately $23.0 million. The company confirmed it no longer has outstanding deficiencies with Nasdaq following recent share issuances and corporate actions. CDT, a data-driven biopharmaceutical development company, reported stockholders' equity of approximately $103 million as of June 30, 2026.
CDT Equity Inc. announced the development of new solid forms and crystal structures of its existing drug compounds with improved stability, solubility, and manufacturability. The company has filed patents for new therapeutic uses identified through AI-driven analysis, targeting underserved patient populations. CDT plans to advance these findings through laboratory models and pursue licensing partnerships, aiming to create a differentiated, patent-protected portfolio with reduced scientific risk.
Filed: 2026-08-21 AccNo: 0001493152-26-039587 Size: 634 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 9.01: Financial Statements and Exhibits